Karyopharm Therapeutics Inc. Revenue Disclosure
3. Product Revenue
To date, our only source of product revenue has been from the U.S. sales of XPOVIO. The following table summarizes activity in each of the product revenue allowance and reserve categories (in thousands):
|
|
Discounts and |
|
|
Fees, Rebates, |
|
|
Returns |
|
|
Total |
|
||||
Beginning balance as of January 1, 2023 |
|
$ |
2,865 |
|
|
$ |
3,734 |
|
|
$ |
542 |
|
|
$ |
7,141 |
|
Provision related to sales in the current year |
|
|
21,106 |
|
|
|
11,025 |
|
|
|
— |
|
|
|
32,131 |
|
Credits or payments made |
|
|
(21,455 |
) |
|
|
(10,089 |
) |
|
|
(224 |
) |
|
|
(31,768 |
) |
Ending balance as of December 31, 2023 |
|
|
2,516 |
|
|
|
4,670 |
|
|
|
318 |
|
|
|
7,504 |
|
Provision related to sales in the current year |
|
|
29,346 |
|
|
|
18,021 |
|
|
|
3,172 |
|
|
|
50,539 |
|
Credits or payments made |
|
|
(27,632 |
) |
|
|
(8,848 |
) |
|
|
(1,635 |
) |
|
|
(38,115 |
) |
Ending balance as of December 31, 2024 |
|
|
4,230 |
|
|
|
13,843 |
|
|
|
1,855 |
|
|
|
19,928 |
|
Provision related to sales in the current year |
|
|
25,843 |
|
|
|
19,003 |
|
|
|
1,335 |
|
|
|
46,181 |
|
Provision related to sales in the prior year |
|
|
— |
|
|
|
1,305 |
|
|
|
4,519 |
|
|
|
5,824 |
|
Credits or payments made |
|
|
(26,799 |
) |
|
|
(10,603 |
) |
|
|
(3,537 |
) |
|
|
(40,939 |
) |
Ending balance as of December 31, 2025 |
|
$ |
3,274 |
|
|
$ |
23,548 |
|
|
$ |
4,172 |
|
|
$ |
30,994 |
|
Discounts and chargebacks are recorded as reductions of accounts receivable, and returns, fees, rebates, and other incentives are recorded as a component of accrued expenses and other liabilities.
As of December 31, 2025 and 2024, net product revenue of $22.7 million and $27.8 million, respectively, was included in accounts receivable, net.Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Feb 13, 2026 | Showing above |
| 2024 | Feb 19, 2025 | |
| 2023 | Feb 29, 2024 | |
| 2022 | Feb 17, 2023 | |
| 2021 | Mar 1, 2022 | |
| 2020 | Feb 24, 2021 | |
| 2019 | Feb 26, 2020 | |
About Revenue Disclosures
Revenue disclosures under ASC 606 explain how a company identifies performance obligations, allocates transaction prices, and determines when revenue is recognized. This section is essential for understanding whether reported revenue reflects genuine economic activity or aggressive accounting choices. Analysts examine the mix of point-in-time versus over-time recognition, which directly affects revenue timing and comparability.
Key signals: rising contract liabilities (deferred revenue) suggest strong future revenue visibility, while declining contract assets may indicate slowing project milestones. Watch for variable consideration estimates — rebates, returns, and performance bonuses that require management judgment. Significant changes in disaggregated revenue by geography or product line can reveal shifting business mix before it appears in headline numbers. Compare revenue growth against contract liability growth to assess sustainability, and scrutinize any changes in the timing of recognition that coincide with earnings pressure.